两种胰岛素类似物治疗2型糖尿病的比较

目的探讨预混胰岛素类似物门冬胰岛素30注射液（诺和锐30）和长效胰岛素类似物甘精胰岛素注射液（来得时）治疗2型糖尿病的疗效和安全性。方法 83例初诊2型糖尿病随机分成2组,分别给予诺和锐30每天2次及来得时每天1次治疗12周,观察治疗前后空腹血糖（FPG）、餐后2小时血糖（PPG）、糖化血红蛋白（HbA1c）的变化,比较两组血糖达标率、低血糖的发生率。结果诺和锐30组HbA1c较来得时治疗组明显下降,HbA1c（7.42±1.38）%vs（8.31±1.82）%（P〈0.05）。诺和锐30组PPG显著低于来得时组,（7.82±4.18）mmol/L vs（8.21±3.90）mmol/L（P〈0.05）。诺和锐30组PPG达标率更高,83.0%vs 56.1%（P〈0.05）,达标时间更短,（7.85±1.48）天vs（8.25±2.46）天,但低血糖事件较来得时组略高,26.2%vs 12.2%（P〈0.05）。诺和锐30组胰岛素用量高于来得时组,（0.61±0.24）U/kg vs（0.50±0.27）U/kg（P〈0.05）,体质量增加也较明显,（5.6±4.6）kg vs（3.0±4.3）kg（P〈0.05）。结论诺和锐30每天2次治疗比来得时每天1次治疗能更有效地降低血糖,血糖达标时间更短,但低血糖发生率略高。

Comparison of premix and basal insulin premix analogue therapy in type 2 diabetes mellitus patients

Objective To compare the efficacy and safety of biphasic insulin aspart 30(BIAsp30) given twice daily with once-daily insulin glargine in type 2 diabetes mellitus. Methods 83 patients with newly diagnosed type 2 diabetes mellitus were randomized to receive either aspart 30 twice daily or glargine once daily for 12 weeks.The level of fasting plasma glucose(FPG),2 hour postprandial glucose(PPG),glycosylated hemoglobin A1c(HbA1c) were compared before and after treatment.At the end of the trial,the difference i...